GREY:ATBPF - Post by User
Comment by
WalkOverTheStrton Aug 17, 2021 9:59am
243 Views
Post# 33716320
RE:Sedar report
RE:Sedar reportMaking any calls / predictions imo is a general waste in time until we hear back in Oct. They have more than enough data to review and compare specifically those 3 patients against others. I personally view the duration of a lower dose (75mg) as potential since prior pain relieving studies of Otenal were only 2 weeks and stacked up at or better than 12 week NSAID trials. Still a path. More risk yes. But a path and hopefully they accelerate their other drugs / dose 1H in 2022.
During the course of the absorption, metabolism and excretion (“AME”) study, the Company conducted twice-weekly blood draws and collected other specimens to measure key biomarker and pharmacokinetic data. More than 6,200 samples will be analyzed at five specialized labs in Canada and internationally, providing insight on the drug’s behavior and the potential for effectiveness at lower doses.